Merck (MRK) Net Income Growth (3y) (2012 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
76.51% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
131.31% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
109.43% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
5.72% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
-51.68% |
| Dec 31, 2024 |
296.61% |
| Jun 30, 2024 |
154.32% |
| Mar 31, 2024 |
121.78% |
| Dec 31, 2023 |
-63.17% |
| Sep 30, 2023 |
97.46% |
| Jun 30, 2023 |
-122.28% |
| Mar 31, 2023 |
-4.26% |
| Dec 31, 2021 |
-26.72% |
| Jun 30, 2021 |
-42.16% |
| Mar 31, 2021 |
-16.14% |
| Dec 31, 2020 |
35.79% |
| Sep 30, 2020 |
141.58% |
| Jun 30, 2020 |
-30.29% |
| Mar 31, 2020 |
27.42% |
| Dec 31, 2019 |
-45.50% |
| Sep 30, 2019 |
-4.48% |
| Jun 30, 2019 |
29.80% |
| Mar 31, 2019 |
36.31% |
| Dec 31, 2018 |
21.88% |
| Sep 30, 2018 |
2.26% |
| Jun 30, 2018 |
35.62% |
| Mar 31, 2018 |
-8.21% |
| Dec 31, 2017 |
-28.90% |
| Sep 30, 2017 |
-27.25% |
| Jun 30, 2017 |
-1.36% |
| Mar 31, 2017 |
-3.49% |
| Dec 31, 2016 |
-39.59% |
| Sep 30, 2016 |
23.91% |
| Jun 30, 2016 |
8.94% |
| Mar 31, 2016 |
-11.24% |
| Dec 31, 2015 |
1.15% |
| Sep 30, 2015 |
1.27% |
| Jun 30, 2015 |
-27.69% |
| Mar 31, 2015 |
-18.46% |
| Dec 31, 2014 |
68.08% |
| Sep 30, 2014 |
-21.25% |
| Jun 30, 2014 |
-0.34% |
| Mar 31, 2014 |
17.36% |
| Dec 31, 2013 |
35.59% |
| Sep 30, 2013 |
45.67% |
| Jun 30, 2013 |
6.23% |
| Mar 31, 2013 |
65.11% |
| Dec 31, 2012 |
-58.24% |
| Sep 30, 2012 |
55.31% |
| Jun 30, 2012 |
66.54% |
| Mar 31, 2012 |
30.08% |